Emetic potential of daily oral etoposide

Supportive Care in Cancer

Volumn 14, Issue 12, 2006, Pages 1262-1265

  Einhorn, Lawrence H ^a,b   Brames, Mary J ^a  

^a INDIANA UNIVERSITY   (United States)

^b WALTHER CANCER INSTITUTE   (United States)

Author keywords

Antiemetics; Chemotherapy induced nausea and vomiting; Oral etoposide

Indexed keywords

ANTIEMETIC AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; SEROTONIN 3 ANTAGONIST;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG MEGADOSE; GERM CELL TUMOR; HUMAN; MALE; MONOTHERAPY; NAUSEA AND VOMITING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; QUESTIONNAIRE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ETOPOSIDE; HUMANS; MALE; NAUSEA; PROSPECTIVE STUDIES; VOMITING;

EID: 33751304141     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0106-x     Document Type: Article

References (12)

1. Bhatia S, Abonour R, Porcu P et al (2000) High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18:3346-3351
2. Cooper MA, Einhorn LH (1995) Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 13:1167-1169
3. Einhorn LH (1990) Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8:731-735
4. Einhorn LH (2002) Curing cancer: testicular cancer. Proc Natl Acad Sci U S A 99:4592-4595
5. Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics evidence-based, clinical practice guidelines. J Clin Oncol 17:2971-2994
6. Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 13:80-84
7. Herrstedt J, Koeller JM, Roila F et al (2005) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:97-103
8. Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15:103-109
9. Miller JC, Einhorn LH (1990) Phase II study of daily oral etoposide is refractory germ cell tumors. Semin Oncol 17:36-39
10. Roila F, Warr D, Clark-Snow RA et al (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:104-108
11. Ross W, Rowe T, Glisson B et al (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44:5857-5860
12. Vardy JL, Chiew K, Galica J, Pond GR, Tannock IF (2005) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011-1015